Celyad Oncology
Letter to Shareholders – January 2020
January 28, 2020 By Celyad
Dear Shareholder,
Throughout the past year, we've generated a tremendous amount of positive change and focus throughout the company, which has positioned us to deliver new clinical data across our development pipeline in 2020. Each of our programs continue to build momentum as we move towards our goal of bringing cancer patients with poor prognosis innovative new CAR-T therapies. These advancements speak directly to our position as a leader in the CAR-T cell therapy industry.
This exciting time in Celyad's history is only possible due to the hard work and dedication of each and every one of our team members, patients, physicians and collaborators. And of course, we must thank you, our shareholders, for your continued support and investment in the company as we look towards continued success and progress in 2020 and beyond.
Download press release(s)
Filed Under: Letter to Shareholders
Cookie Policy | Privacy Policy | Terms of Use
Our website uses cookies including analytics cookies to help us improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good-functioning of our website. You can find more information about the cookies we use by visiting our Cookie Policy.I AcceptI RefuseCookie Policy